Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
. {- Y- V+ J+ _( D, O$ ]" N/ t
! Z" Z( v6 Q8 l" f4 U U0 I2 Q+ C$ i
Sub-category:
+ M: f# h/ Q' s( n# uMolecular Targets ) R0 X1 `2 E P0 d1 n7 n
1 K8 ~* J) _- L3 b- O
1 Z) d5 h. F8 @, KCategory:
% F! O3 k# c9 ]# D2 KTumor Biology * O% {; [) c2 o' [
; C0 p, c6 y; \4 b4 z
) B3 t$ V! z3 z% v$ N$ J# ?Meeting:
( V9 x3 p, {8 s. s2011 ASCO Annual Meeting
+ c% h6 e' M3 s* l: Y$ w/ X
+ y$ R6 \* s3 B/ r8 d. s- S6 j2 q8 q
Session Type and Session Title: P4 r6 ]- f" a3 k2 N- a$ \
Poster Discussion Session, Tumor Biology
5 g- Q' C4 R+ s2 Z% Q
* R! ^3 ]1 o; D J; x1 E5 a2 w; \2 Q0 H7 j" r
Abstract No:
% a" l) O+ B9 D, {, m* K10517
7 Z. z2 S9 X. W9 C6 _4 R0 g$ i* n2 b- ^% m
+ e) m7 G$ z3 A7 ?Citation:
8 W) M, k: A1 `# ]: OJ Clin Oncol 29: 2011 (suppl; abstr 10517) : p+ U. D& ~) F- k. F. p
- P: T6 v( Q, C5 b
% f+ }, o+ o' p1 l F! U& \Author(s):8 @0 J4 ~3 O1 c
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
% n+ u' L& X5 G" V& y! X% p4 h0 g" G6 F" K
! |! ]$ @9 N6 y8 w. S3 \
a+ V4 R% e" M3 w( q4 {5 d8 y5 }
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings., a( a0 Y( M7 A8 r" |
2 \( B0 [2 q4 g8 ~; g f& G$ _
Abstract Disclosures
" H g) L2 e2 G( T0 V# Y5 e% b% B( }; v" r L; @ ]
Abstract:
4 ~4 @# I# \/ D) R
& ~' A4 u; S8 K' C4 S8 g; Q& L- l0 g
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
' P' d" `5 T3 u
% g4 ]6 H# q( M: [1 ^ / J5 _+ N, B$ L3 F# E6 _
|
21突变 特罗凯5年5个月后奥西不到一
Hi 各位，
求助
基本情况：女 64岁 无吸烟史，
2018年确诊，右肺切除术后，当时分期
右肺上叶切除，术前术后对比
今年2月21日手术前发现占位40×31，术后辅助治疗发现团块影82×75？谁能帮我看看两份
5年奥希还是复发了，伴有恶性胸水该
家母2020年直接开始服用奥西替尼，效果一直很好，最近两个月出现胸水以及锁骨淋巴肿大
父亲奥西+卡马耐药后应该如何选择？
2021年9月确诊肺腺癌，基因检测结果EGFR19缺失，服用奥希替尼。2024年3月CT影像检查出
晚期肺癌13年靶向轮换之路，我总结9
讲述者：不怕辣椒不怕癌整理者：雪漓
上篇文章中分享了我家13年抗癌经历以及心态成长
% H8 H$ `$ C# v: c- R0 c5 Z
显身卡
